Agios Pharma (AGIO) Gets a Hold Rating from Oppenheimer

By Austin Angelo

In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Agios Pharma (NASDAQ: AGIO). The company’s shares opened today at $82.38.

Cann commented:

“AG-881 is a promising early-stage molecule. We have not included any impact from AG-881 in our outlook through 2022. Data presented in June this year were highly encouraging in gliomas. The dissolution of the Celgene collaboration for AG-881 will allow Agios to develop this compound in gliomas, while retaining sole global rights. Agios is expected to have to pay a small royalty to Celgene if AG-881 becomes commercial.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 25.3% and a 54.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agios Pharma with a $106.75 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $99.82 and a one-year low of $51.62. Currently, Agios Pharma has an average volume of 330.2K.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.